Header Logo

Connection

CURTIS A PETTAWAY to Imatinib Mesylate

Back to Details
This is a "connection" page, showing publications CURTIS A PETTAWAY has written about Imatinib Mesylate.
CURTIS A PETTAWAY
Connection Strength
0.061
Imatinib Mesylate
  1. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan; 181(1):81-7; discussion 87.
    View in: PubMed
    Score: 0.061
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.